BrainStorm Cell Therapeutics Receives Refusal to File Letter from FDA for its New Biologics License Application for NurOwn for the treatment of ALS

/PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of cellular therapies for neurodegenerative diseases, today announced...

Related Keywords

California ,United States ,University Of Massachusetts Medical School ,Massachusetts ,Irvine ,John Mullaly ,Anthony Windebank ,Tony Windebank ,Robert Brown ,Namita Goyal ,Chaim Lebovits ,Robert Baloh ,Seanm Healey ,Jonathan Katz ,Robert Miller ,Matthew Burford ,Lisa Guiterman ,James Berry ,California Institute For Regenerative Medicine ,Brainstorm Cell Therapeutics Inc ,Lifesci Advisors ,Drug Administration ,Nasdaq ,Program In Neurotherapeutics ,University Of Massachusetts Medical School Prof ,Prnewswire Brainstorm Cell Therapeutics Inc ,Sinai Medical Center Dr ,National Ms Society ,European Medicines Agency ,Research Symposia ,California Pacific Medical Center Prof ,University Of California Irvine Dr ,Storm Cell Therapeutics ,New Biologics License Application ,Chief Executive Officer ,Nurown Phase ,Massachusetts Medical School ,Merit Cudkowicz ,Massachusetts General Hospital ,Julieanne Dorn Professor ,Harvard Medical School ,James Pape Adams Foundation Professor ,Nerve Supplemental File ,Nerve Erratum ,Town Study ,California Irvine ,Cedars Sinai Medical Center ,California Pacific Medical Center ,Mayo Clinic ,Nathan Staff ,Orphan Drug ,California Institute ,Regenerative Medicine ,Harbor Statement ,Brainstorm Cell Therapeutics ,Sci Advisors ,